Great post from Ifub.--Alright, let's recap- in just a

New Post Public Reply Private Reply Replies (0) Message Board
Hnbadger1
Great post from Ifub.--Alright, let's recap- in just a short time AMBS went from owning a small IP portfolio on MANF to where we are today. So where are we exactly? Right now our CEO is amongst the world's elite in the Alzheimer's space. We have a diagnostic which is in the running to be the first blood diagnostic in this space. We are still on track to be commercialized this year for trials. This is a stepping stone for the world market. By gaining accreditation with the trails will gain not only exposure but acceptance within the health care space. By just being in the middle of this conference the main players are taking note. It's not time to expose the agenda just yet. Why? Well in the middle of the conference is also big pharma (where we all will make our money from AMBS- I mean real money). Gerald has managed to be in the same room as them for years now. At first he was not known and was paid no attention to. Now these guys are seeing him build from what was a meek IP portfolio to it being way more extensive. They have seen a progression. He now has a diagnostic which is being primed for other applications. He has acquired a phase 2b drug. Positioning the study to be submitted, Identified reimbursement codes, putting together applications for various orphan designations, aligning a program diabetes, set up alliances with key incubator's which will not only develop MANF and Lympro but identify future therapies and technologies, moved the lab to Jansen (huge), opened up Geneva offices, solidified a powerful board of directors, has 18 employees working to further develop the plan, has cash in the books, access to $20 million more dollars and will receive an additional $5 million dollars in new warrant proceeds. Remember in the filings a bit ago when JP Morgan mentioned they may now buy in addition to another major fund making the same declaration? People are paying attention. He now is in the middle of the world's elite including big pharma and they all see what he has done. He is in talks for a partnership which he has publicly stated. Imagine if he would of done a partnership a year ago. How much shareholder would have been lost? Jason napadano has a price target of .20. This does not include eltropozine or the orphan application or reimbursement or a partnership, or a diabetes program. Some expectations that we have are off- not solid thinking... Would be like telling the other team what you are about to call. The price isn't down because of the conference, it is down because we are selling!

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Memoir 'Pinball' Explores Life's Unpredictable Momentum

Updated Category News Views 40

Funny how some folks think life has a road map. Let me tell you, it's more like a pinball machine, barely controllable and ready to surprise you with a tilt at any moment. And that's the essence of Marshall Barber's new memoir, 'PINBALL: Remembrances of a Flaneur.' Life's Roulette: Choices and Chance Barber takes readers on a raw ride through the byways of a life...

Continue Reading
YR Fitness Rolls Out Innovator's Iron at FIBO 2027

Updated Category News Views 73

A New Era of Strength Training Equipment? That's the question I asked myself when I heard about YR Fitness showcasing their latest gym gear at FIBO 2027. This isn't just another batch of machines rolling off the production line. YR Fitness has become quite the icon in China for strength equipment, and they're dead set on shaking up the market in Cologne, Germany from...

Continue Reading
PG&E, Edison Push Liability Cap Amid Firestorm

Updated Category News Views 93

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

Continue Reading
Oracle's $20 Billion Offering: What Investors Need to Know

Updated Category News Views 133

Oracle's Big Play: A $20 Billion Offering Nobody said playing in the big leagues was easy, and Oracle seems to be doubling down on that idea. Today, they spilled the beans on their ambition to rake in a cool $20 billion through an offering of common stock and senior notes. For those of us who keep a close eye on NYSE:ORCL, this is more than just a number—it's a signal...

Continue Reading
Alfa Laval's Market Outlook: Strategic Plans Ahead

Updated Category News Views 0

Alfa Laval's Vision for the Future Alfa Laval is gearing up for a dynamic Capital Markets Day on November 18, 2026. The Swedish engineering giant, renowned for heat transfer, separation, and fluid handling solutions, is setting the stage to outline bold strategies and ambitious targets. Investors should pay attention, as the company's roadmap charts a course towards a SEK...

Continue Reading
ALS Research Gains Momentum as ACT for ALS Law Signed

Updated Category News Views 42

A Major Stride in ALS Advocacy Today's not your usual day at the office for the folks championing the fight against ALS. With the President putting pen to paper, the ACT for ALS Act just turned into law, sending ripples through the community. Let me tell ya, legislation like this doesn't float by on a cloud—it's the result of grit, sleepless nights, and a dash of...

Continue Reading
WareSpace Expands in U.S. with Key Site Acquisitions

Updated Category News Views 90

WareSpace's National Growth Strategy: A New Expansion Chapter They say everything's bigger in Texas, but WareSpace is showing that smaller can be mighty impactful too. With its shrewd acquisition of sites in Houston's Inner Loop and Fremont's Warm Springs corridor, WareSpace is playing it smart, appeasing that roaring demand for tiny but mighty warehouse spaces across...

Continue Reading
LITE, RRC, SGRY: Are Shareholders Getting Shortchanged?

Updated Category News Views 23

What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...

Continue Reading
Kia's Thunderous October Sales Surge: What's Under the Hood?

Updated Category News Views 120

Electric Pulse: Kia's Electrified Dreams Soar No one said the road to the top is easy, yet Kia America is cruising along with six straight months of shattering sales records. October's monumental figures paint the picture clear as a bell — 80,008 units dispatched to eager drivers, with electrified and hybrid models zooming to new heights. It ain't just the same old...

Continue Reading
TEKLYNX 2026: Revolutionizing Barcode Labeling Tech

Updated Category News Views 55

In the ever-evolving world of supply chain technology, a big move by TEKLYNX is making waves. The 2026 version of their barcode labeling software isn't just an upgrade—it's a full-blown transformation. They've fine-tuned their suite to align with the latest industry standards and integrated fresh capabilities that scream future-proofing. TEKLYNX's Game-Changing Upgrades...

Continue Reading

Top 5 Most Recently Viewed Articles

Tsubame BHB Recognized for Pioneering Ammonia Solutions Globally

Updated Category News Views 169

Tsubame BHB Earns Recognition in Global Cleantech Innovation Tsubame BHB Co., Ltd. has recently made headlines for being named one of the standout companies in the 2025 Global Cleantech 100 list, an accolade that underscores its innovative approach to ammonia manufacturing. This recognition highlights the company's commitment to harnessing low-temperature and low-pressure...

Continue Reading
Transforming $1000 into a Wealthy Investment with ONTO

Updated Category News Views 67

Smart Investment Growth: The Rise of Onto Innovation In the last five years, Onto Innovation (NYSE: ONTO) has emerged as a remarkable player in the stock market, significantly surpassing average market gains. With an impressive annualized return of 42.16%, those who invested in ONTO have experienced extraordinary growth. The Power of Compound Returns Understanding...

Continue Reading
Celebrating Dr. Beatrice Setnik: A PharmaVoice 100 Honoree

Updated Category News Views 222

Dr. Beatrice Setnik Honored as PharmaVoice 100 Winner Altasciences is thrilled to share that Dr. Beatrice Setnik has been honored as a PharmaVoice 100 winner. With almost two decades of expertise in clinical drug development, especially regarding abuse potential studies, Dr. Setnik's leadership qualities have made a notable impact in the field. As the Chief Scientific...

Continue Reading
Momentus Secures Major Defense Contract and Financing Boost

Updated Category News Views 171

Momentus Inc Achieves Significant Milestone Momentus Inc (NASDAQ: MNTS) has recently made headlines with a notable increase in its stock value after the company secured inclusion in a crucial defense contract program in the U.S. This achievement not only highlights the strategic importance of the company’s offerings but also brings in new opportunities for growth as...

Continue Reading
HCI Group's Remarkable Q2 2025 Financial Highlights Explained

Updated Category News Views 137

Exceptional Financial Results for HCI Group in Q2 2025 HCI Group, Inc. (NYSE:HCI) has reported outstanding financial performance for the second quarter of 2025, showcasing remarkable metrics that highlight its commitment to profitability and shareholder value. With a pre-tax income of $94.4 million and a net income of $70.3 million, up from $54.1 million in the second...

Continue Reading